arrow
H

Hien Liu

department of blood and marrow transplantation and cellular therapy
H指数:24
被引数:2,335

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel

年龄作为接受阿西替尼胞苷治疗的大B细胞淋巴瘤患者神经认知表现的调节变量

2026-09-080
OAAI
Product-Intrinsic NF-κB–Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma

产品内在的NF-κB驱动的转录程序与多发性骨髓瘤中CAR-T应答的持久性相关

Blood
IF23.1
2026-06-220
PRE
Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy

镰状细胞病基因治疗:移植与细胞治疗学会和国际细胞与基因治疗学会的实践建议

2026-03-280
OAAI
Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia

肥胖及基于体重的化疗剂量调整对急性髓系白血病异基因造血细胞移植结局的影响

2025-10-200
PRE
Quality indicators for cell collections for immune effector cell and gene therapy: Recommendations from the American Society for Apheresis

细胞采集的质量指标:用于免疫效应细胞和基因治疗的建议——来自美国血细胞分离学会

2025-08-290
PRE
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide

Letermovir可降低接受移植后环磷酰胺治疗的HLA匹配和错配异基因造血细胞移植患者中的巨细胞病毒水平。

2025-07-050
PRE
Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma

增强的CAR-T细胞功能与线粒体健康性源自于多发性骨髓瘤中更早期的未分馏干细胞产品

2025-04-180
PRE
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma

接受抗BCMA CAR-T治疗的复发性和难治性多发性骨髓瘤患者的心血管不良事件和结局

2025-04-140
OA
Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)

Venetoclax (VEN)为基础的治疗方案在t(11;14)-阳性复发/难治性多发性骨髓瘤(R/R MM)中的活性和安全性

BLOOD
IF23.1
2024-11-050
PRE
Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

标准治疗(SOC)Elranatamab在复发性/难治性多发性骨髓瘤(RRMM)患者中的安全性与有效性:一项单中心经验

BLOOD
IF23.1
2024-11-050
PRE
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
2024-10-011
PRE
Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

首次反应的自体造血细胞移植巩固与淋巴结周围T细胞淋巴瘤患者的生存期延长有关

2024-09-010
PRE
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations
2024-03-280
OAAI
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis

抗BCMA car-t细胞治疗老年多发性骨髓瘤的安全性和有效性: 系统评价和meta分析

2024-03-0115
PRE
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

白蛋白和CRP的简单评分预测接受car-t治疗的多发性骨髓瘤患者的高度毒性

2024-03-017
PRE
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
2024-02-015
PRE
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
2023-08-0913
OAAI
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
2022-12-1451
OAAI